Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 19

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Type 2 diabetes mellitus85Type 1 diabetes mellitus41Endocrine ophthalmopathy26Neuroblastoma26Obesity24Diabetes mellitus21Neuroendocrine tumour19Overweight18Gastroenteropancreatic neuroendocrine tumour disease16Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Chronic kidney disease8Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+189

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Gastroenteropancreatic neuroendocrine tumour disease

Not yet recruiting

68Ga-DOTATATE PET/CT Prognostic Assessment in Patients with Well-Differentiated Grade 2 Gastroenteropancreatic Neuroendocrine Tumors Treated with 177Lu-oxodotreotide and Edotreotide

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Edotreotide
  • Sponsor:Centre De Lutte Contre Le Cancer Eugene Marquis

Type 2 diabetes mellitus+2

Not yet recruiting

Effect of semaglutide, acetylsalicylic acid, and clopidogrel on blood clotting in patients with diabetes or overweight with cardiovascular disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Type 2 diabetes mellitus

Not yet recruiting

A study to evaluate the effectiveness of NNC0662-0419 and semaglutide in people with type 2 diabetes

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · Healthy volunteers
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Hypoparathyroidism

Not yet recruiting

Study evaluating the effects of palopegteriparatide and alfacalcidol on quality of life and brain function in patients with hypoparathyroidism

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alfacalcidol
  • Sponsor:Region Midtjylland

Diabetic foot+1

Not yet recruiting

Comparing local gentamicin or vancomycin hydrochloride to a drug combination for patients with diabetic foot osteomyelitis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Pirkanmaan hyvinvointialue

Type 1 diabetes mellitus

Not yet recruiting

Study of the efficacy and safety of ladarixin and rabbit anti-human thymocyte immunoglobulin in adolescents and adults with new-onset type 1 diabetes

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ladarixin
  • Sponsor:Ospedale San Raffaele S.r.l.

Hypoparathyroidism

Not yet recruiting

A study to evaluate the safety and effects of palopegteriparatide in adolescents with chronic hypoparathyroidism

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Palopegteriparatide
  • Sponsor:Ascendis Pharma Bone Diseases A/S

Primary bilateral macronodular adrenal hyperplasia

Not yet recruiting

Study of the effect of metyrapone in patients with mild Cushing syndrome caused by primary bilateral macronodular adrenal hyperplasia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Metyrapone
  • Sponsor:Assistance Publique Hopitaux De Paris

Congenital growth hormone deficiency

Not yet recruiting

Study of the effects of ibutamoren mesilate in prepubertal children with growth hormone deficiency

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ibutamoren Mesilate
  • Sponsor:Lumos Pharma Inc.

Diabetic neuropathy

Not yet recruiting

Study of the effectiveness and safety of alpha-lipoic acid and benfotiamine for the treatment of symptoms in patients with diabetic neuropathy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Benfotiamine
  • Sponsor:Woerwag Pharma GmbH & Co. KG

Neuroendocrine carcinoma metastatic

Not yet recruiting

A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Hospices Civils De Lyon

Endocrine ophthalmopathy

Not yet recruiting

A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide48 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsMetformin Hydrochloride13 clinical trialsMetformin12 clinical trialsSodium Chloride12 clinical trialsCisplatin11 clinical trialsEtoposide11 clinical trialsLutetium (177LU) oxodotreotide11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.